MolNFT v1 · #139555 · protein
Tead in complex with fragment
5XJD · Transcriptional enhancer factor tef-3: “Tead in complex with fragment”. X-ray diffraction, 1 ligand (87L), 5 pockets (best druggability 0.82). MolNFT v1 #139555 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 5XJD
- Type
- protein
- Length
- 421 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Transcriptional enhancer factor tef-3
- UniProt
- Q62296
- Ligands
- 87L
- Pockets
- 5 · best druggability 0.82
Structure
x-ray diffraction · 2 distinct chains · 18% helix, 50% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Transcriptional enhancer factor tef-3 | protein | 209 | 17% helix, 51% strand | Q62296 |
| B | Transcriptional enhancer factor tef-3 | protein | 212 | 18% helix, 50% strand | Q62296 |
Ligands and binding sites
- 87L · (2S)-2-phenyl-2-pyrrol-1-yl-ethanoic acid · ligand · chains A, B
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 275 | 0.82 | 0.93 | 35 | empty |
| 2 | 304 | 0.81 | 0.91 | 44 | empty |
| 3 | 228 | 0.75 | 0.88 | 28 | 87L |
| 4 | 63 | 0.33 | 0.76 | 23 | empty |
| 5 | 73 | 0.32 | 0.74 | 15 | empty |
Interfaces
1 interface between chains.
- A–B · 636 Ų buried · 6 hydrogen bonds · protein-protein
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q62296
- Elsewhere: RCSB PDB 5XJD · PDBe 5XJD · UniProt Q62296
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.